Paper Details

  1. Home
  2. Paper Details

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.

Author: KanekoGenki, KawaguchiYutaka, KomatsuYasuhiro, KondoKazuoki, NangakuMasaomi, OtsukaMakiko, TakabeSouichirou, UetaKiichiro

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This phase 3 study evaluated the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia in Japanese CKD patients undergoing peritoneal dialysis. Vadadustat was well-tolerated and effective in controlling hemoglobin levels within the target range.
Paper Details　
Original Abstract of the Article :
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open-label, 24-week single-arm study evaluated the efficacy and safety of vadadustat in 42 Japanese CKD patients with anemia undergoing...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451920/

データ提供：米国国立医学図書館（NLM）

Vadadustat: A Beacon of Hope in the Desert of Anemia

This research explores the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in treating anemia in patients with chronic kidney disease (CKD) undergoing peritoneal dialysis. The study, conducted in Japan, involved 42 CKD patients with anemia who received oral vadadustat for 24 weeks. The primary outcome was hemoglobin (Hb) level, which was successfully controlled within the target range. The study also assessed safety and found that vadadustat was generally well tolerated, with the most frequent adverse event being catheter site infections, unrelated to the treatment. The study concludes that vadadustat is a promising treatment option for anemia in Japanese CKD patients undergoing peritoneal dialysis.

A Lifeline in the Desert of Anemia

This study offers a glimmer of hope for individuals navigating the challenging desert of chronic kidney disease (CKD) and its associated anemia. Vadadustat, like a reliable oasis, provides a well-tolerated and effective treatment option for controlling hemoglobin levels. The study's findings could have significant implications for improving the quality of life for CKD patients.

Finding a Path Through the Desert of CKD

This study emphasizes the importance of addressing anemia in CKD patients, a critical factor in their overall well-being. Vadadustat emerges as a valuable tool for managing anemia, offering a potential path to improved health and quality of life for individuals navigating the complexities of CKD. The study encourages further research and clinical application of this promising treatment option.

Dr.Camel's Conclusion

Vadadustat, like a beacon of hope in the vast desert of anemia associated with chronic kidney disease (CKD), provides a promising and well-tolerated treatment option. This research highlights the effectiveness of vadadustat in controlling hemoglobin levels, offering a potential path to improved health and quality of life for individuals facing the challenges of CKD.

Date :
  1. Date Completed 2022-01-17
  2. Date Revised 2022-01-17
Further Info :

Pubmed ID

33283981

DOI: Digital Object Identifier

PMC8451920

Related Literature

Article Analysis
・Effects of vadadustat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.